bluebird bio Inc (NAS:BLUE)
$ 0.6063 0.0323 (5.63%) Market Cap: 116.86 Mil Enterprise Value: 240.32 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 25/100

bluebird bio Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 10:20PM GMT
Release Date Price: $3.21 (-16.62%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

My name is Jason Gerberry. I'm on pleased to be introducing bluebird bio and CEO, Andrew Obenshain; and Tom Klima, Chief Commercial Officer. So gentlemen, thanks so much for joining us.

Andrew Obenshain
bluebird bio, Inc. - President, CEO & Director

Thank you for having us.

Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

So I guess not too long from the spin or separation from what was still bluebird bio but had the oncology programs and now the gene therapy programs, and now you're able to focus in on gene therapy and specifically your programs, which are pretty far along from a development standpoint and derisked now in front of the FDA, at least 2 of them for some FDA advisory panels in a month.

So a lot going on. So maybe it might be a good place to start. Unless you want to maybe orient the investors who maybe don't know the company as well. If you have any 1 or 2 short

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot